Skip to content
10-Q

Quarterly Report

ACRO BIOMEDICAL CO., LTD. ACBM

0001640334-25-001279

← back to feed
Filed
Jul 23, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Current Liabilities Q2 2024 · Jun 30, 2024 $308.03K
Current Liabilities Q2 2024 · Dec 31, 2023 $288.58K
Total Liabilities Q2 2024 · Jun 30, 2024 $321.68K
Total Liabilities Q2 2024 · Dec 31, 2023 $315.47K
Current Assets Q2 2024 · Jun 30, 2024 $926
Current Assets Q2 2024 · Dec 31, 2023 $1.63K
Total Assets Q2 2024 · Jun 30, 2024 $45.28K
Total Assets Q2 2024 · Dec 31, 2023 $58.46K
Rd Expense Q2 2024 · Jun 30, 2024 $0
Rd Expense Q2 2024 · Jun 30, 2024 $0
Rd Expense Q2 2024 · Jun 30, 2023 $1.88M
Rd Expense Q2 2024 · Jun 30, 2023 $4.4M
Shares Diluted Q2 2024 · Jun 30, 2023 60.04M sh
Shares Diluted Q2 2024 · Jun 30, 2023 60.04M sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$3.32K
Stockholders Equity Q2 2024 · Jun 30, 2023 $339.65K
Stockholders Equity Q2 2024 · Mar 31, 2023 $410.9K
Stockholders Equity Q2 2024 · Dec 31, 2022 $486.37K
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.05
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.12
Sga Expense Q2 2024 · Jun 30, 2023 $1.32M
Sga Expense Q2 2024 · Jun 30, 2023 $2.8M
Net Income Q2 2024 · Jun 30, 2023 −$3.2M
Net Income Q2 2024 · Jun 30, 2023 −$7.2M
Net Income Q2 2024 · Mar 31, 2023 −$4M
Operating Income Q2 2024 · Jun 30, 2023 −$3.19M
Operating Income Q2 2024 · Jun 30, 2023 −$7.2M
Revenue Q2 2024 · Jun 30, 2023 $0
Revenue Q2 2024 · Jun 30, 2023 $0